IQVIA Holdings Inc. $IQV Stock Position Trimmed by Sei Investments Co.

Key Points

• Sei Investments Co. reduced its holdings in IQVIA Holdings Inc. by 4.5%, resulting in ownership of 82,624 shares valued at approximately $16.13 million as of the latest SEC filing.
• IQVIA's stock has been subject to various target price changes by analysts, with offerings ranging from a low of $160 to a high of $232, reflecting a mixed outlook with the consensus target price at $228.62.
• In the latest quarter, IQVIA reported an EPS of $2.81, surpassing analyst expectations, with revenue reaching $4.02 billion, a 5.3% increase compared to the previous year.

Sei Investments Co. trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 82,624 shares of the medical research company's stock after selling 3,879 shares during the period. Sei Investments Co.'s holdings in IQVIA were worth $16,129,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in IQV. Continuum Advisory LLC increased its holdings in shares of IQVIA by 3.7% in the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after buying an additional 64 shares during the period. Ballentine Partners LLC boosted its position in shares of IQVIA by 4.9% in the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock worth $260,000 after purchasing an additional 69 shares in the last quarter. Independent Advisor Alliance raised its holdings in IQVIA by 4.2% in the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock worth $318,000 after acquiring an additional 72 shares during the last quarter. ST Germain D J Co. Inc. raised its holdings in IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares during the last quarter. Finally, Nemes Rush Group LLC raised its stake in IQVIA by 15.0% during the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock valued at $109,000 after buying an additional 81 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

IQV has been the subject of several analyst reports. Evercore ISI upped their price objective on IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Cowen reaffirmed a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Redburn Partners set a $188.00 price objective on shares of IQVIA in a research note on Friday, May 23rd. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Finally, JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $228.62.

IQVIA Trading Up 0.0%

Shares of NYSE:IQV traded up $0.0270 during mid-day trading on Tuesday, reaching $192.5670. 624,080 shares of the company were exchanged, compared to its average volume of 1,975,821. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The firm has a market cap of $32.74 billion, a price-to-earnings ratio of 27.92, a P/E/G ratio of 2.10 and a beta of 1.30. The firm's 50-day simple moving average is $171.16 and its 200 day simple moving average is $168.34.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period last year, the business earned $2.64 EPS. The company's revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.